Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma

  • Authors:
    • Shiori Kinoshita
    • Masaki Ri
    • Takashi Kanamori
    • Sho Aoki
    • Takashi Yoshida
    • Tomoko Narita
    • Haruhito Totani
    • Asahi Ito
    • Shigeru Kusumoto
    • Takashi Ishida
    • Hirokazu Komatsu
    • Shinsuke Iida
  • View Affiliations

  • Published online on: April 16, 2018     https://doi.org/10.3892/ol.2018.8501
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as a monotherapy against hematological malignancies and is expected to be used in combination with standard therapies for multiple myeloma (MM). To develop a more effective and less toxic combination of immunomodulatory drugs (IMiDs) for therapy, the antitumor effect of sub‑optimal doses of AFU, pomalidomide plus dexamethasone (PD), and the AFU‑PD combination on MM cells were examined in the present study. Two MM cell lines, XG‑7 and U266, with low sensitivity to both PD and AFU monotherapies, were subjected to these combinations and analyzed. Although the cell lines showed a slight reduction in viability with the sub‑optimal doses of each monotherapy, the combination of the treatments resulted in a reduction in cell viability and the progression of apoptosis. Co‑treatment with sub‑optimal doses of PD and AFU enhanced caspase activation and highly suppressed the expression of IKZF1 and IKZF3. In addition, this combination promoted the dephosphorylation and stabilization of 4EBP1, an inhibitor of eIF4E activation, which led to the impairment of eIF4E‑mediated translational activity. Furthermore, AFU showed a sufficient inhibitory effect on the phosphorylation of FOXO1, a tumor suppressor, in monotherapy or in combination with PD, which may be attributable to the activation of FOXO1, the subsequent inhibition of tumor growth, and the induction of cell death. In conclusion, the combination therapy with sub‑optimal doses of PD and AFU exhibited potent antitumor activity in MM cells and may provide a novel strategy for the treatment of patients who experienced intolerable toxicity or insufficient response during IMiD therapy.

Related Articles

Journal Cover

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T. ... Iida, S. (1899). Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncology Letters, 0, 0-0. https://doi.org/10.3892/ol.2018.8501
MLA
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., Komatsu, H., Iida, S."Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma". Oncology Letters 0.0 (1899): 0-0.
Chicago
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., Komatsu, H., Iida, S."Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma". Oncology Letters 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ol.2018.8501